Hemab Aps
Clinical trials sponsored by Hemab Aps, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New study tracks bleeding in von willebrand disease to pave way for better treatments Results expected Dec 2026 (estimated)
- Can a single injection of HMB-003 be safe for humans? a first test begins Results expected Apr 2027 (estimated)
- New hope for bleeding disorder: first human trial of HMB-002 begins Results expected Jul 2027 (estimated)
- New antibody aims to stop bleeding episodes in rare clotting disorder Results expected Aug 2027 (estimated)
-
New shot could tame rare bleeding disorder
Disease control Recruiting nowThis study tests a new drug called sutacimig in 18 adults with a rare inherited bleeding disorder (factor VII deficiency). The drug is given as a single shot under the skin to see if it is safe and can help prevent bleeding. The goal is to find a more convenient treatment option …
Phase 2 • Sponsor: Hemab ApS • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New hope for bleeding disorder: first human trial of HMB-002 begins
Disease control Recruiting nowThis study tests a new medicine, HMB-002, in about 108 adults with von Willebrand disease (types 1 and 2). The goal is to check safety, how the drug moves in the body, and whether it helps control bleeding. It is the first time this drug is being tested in humans, starting with s…
Phase 1/2 • Sponsor: Hemab ApS • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Can a single injection of HMB-003 be safe for humans? a first test begins
Knowledge-focused Recruiting nowResearchers are testing a new experimental drug called HMB-003 in healthy adults aged 18 to 50. The goal is to see how well the body tolerates a single injection and to measure how much of the drug stays in the blood and urine. This first-in-human study focuses on safety and how …
Phase 1 • Sponsor: Hemab ApS • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC
-
New study tracks bleeding in von willebrand disease to pave way for better treatments
Knowledge-focused Recruiting nowThis study is for people aged 16 to 70 with von Willebrand disease (VWD), a bleeding disorder. Researchers will collect information on bleeding events, treatments, and quality of life over time. The goal is to understand the real-world impact of VWD and use this data as a baselin…
Sponsor: Hemab ApS • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC